PHAXIAM Therapeutics Balance Sheet Health
Financial Health criteria checks 3/6
PHAXIAM Therapeutics has a total shareholder equity of €25.6M and total debt of €10.2M, which brings its debt-to-equity ratio to 39.8%. Its total assets and total liabilities are €51.3M and €25.7M respectively.
Key information
39.8%
Debt to equity ratio
€10.20m
Debt
Interest coverage ratio | n/a |
Cash | €10.47m |
Equity | €25.61m |
Total liabilities | €25.70m |
Total assets | €51.31m |
Recent financial health updates
Is ERYTECH Pharma (EPA:ERYP) Using Debt In A Risky Way?
Mar 23ERYTECH Pharma (EPA:ERYP) Has Debt But No Earnings; Should You Worry?
Dec 07Recent updates
Financial Position Analysis
Short Term Liabilities: PHXM's short term assets (€16.2M) exceed its short term liabilities (€15.3M).
Long Term Liabilities: PHXM's short term assets (€16.2M) exceed its long term liabilities (€10.4M).
Debt to Equity History and Analysis
Debt Level: PHXM has more cash than its total debt.
Reducing Debt: PHXM's debt to equity ratio has increased from 1.4% to 39.8% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: PHXM has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if PHXM has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.